News
Lenalidomide maintenance prolongs overall survival after ASCT
Lenalidomide maintenance therapy significantly prolonged overall survival after autologous stem cell transplant in newly diagnosed multiple...
News
Up-front ASCT superior for fit patients with newly diagnosed myeloma
Upfront high-dose melphalan and autologous stem cell transplantation was superior to bortezomib-melphalan-prednisone for fit patients under age 65...
News
Venetoclax achieves responses in CLL refractory to ibrutinib, idelalisib
Key clinical point: Venetoclax can achieve responses in patients who are refractory to ibrutinib. Major finding: The overall response rate was 61...
Video
VIDEO: Adding ixazomib to len-dex boosts progression-free survival in multiple myeloma
Key clinical point: Adding ixazomib to lenalidomide and dexamethasone was associated with a longer progression-free survival and limited...
News
New single-tube assay detects one CLL cell in 1 million leukocytes
Key clinical point: Chronic lymphocytic leukemia cells can be identified at levels as low as 0.0010% with a newly developed and validated single-...
News
In severe hemophilia B, rIX-FP prophylaxis gets good results with less frequent dosing
Key clinical point: Weekly and 14-day prophylaxis regimens with rIX-FP were well tolerated and provided low bleeding rates and target joint...
News
Prelabor cesarean delivery linked to increased risk of childhood ALL
Key clinical point: Prelabor cesarean delivery was associated with an increased risk of childhood ALL, but not AML. Major finding: The odds ratio...
News
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabine
Key clinical point: Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had...
News
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabine
Key clinical point: Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had...
News
FDG-PET guides need for eBEACOPP in advanced Hodgkin’s
Key clinical point: Using FDG-PET imaging to gauge treatment response after the first two rounds of ABVD therapy helps to determine which patients...
News
CUDC-907 enters phase II for relapsed or refractory lymphoma and multiple myeloma
Key clinical point: The CUDC-907 dose to be used in phase II studies will be 60 mg on a 5-days-on/2-days-off dosing schedule. Major finding: Two...
